News & Events
2010 News Archives
- Dr. Min Kang received double recognition: First she was selected for the 2010 TTUHSC President's Young Investigator Award and then she was recognized by the Texas Tech Board of Regents for her outstanding work in TTUHSC graduate student education.
- The article published in the New England J of Medicine in September on the phase III Children's Oncology Group trial adding antibody therapy + cytokines to 13-cis-retinoic acid for therapy of high-risk neuroblastoma has been ranked by the Faculty of 1000 (http://f1000.com) as being in the top 2% of published articles in biology and medicine. The first author of that paper is Dr. Alice Yu of UCSD and Dr. Reynolds, the TTUHSC Cancer Center Director, is a co-author.
June 17, 2010
- Registration for the Innovations in Cancer Prevention and Research Conference is now open! Read More»
May 7, 2010
- The Cancer Prevention and Research Institute of Texas (CPRIT) presented a check to Texas Tech University Health Sciences Center in the amount of $1,344,300. The check was accepted by Texas Tech University System Chancellor Kent Hance. Read More»
April 17-18, 2010
- Cancer Center members are presenting their research at the AACR meeting in Washington, D.C. this weekend and next week. Click to view the 2010 AACR presentations .
January 20, 2010
- The Cancer Prevention and Research Institute of Texas (CPRIT) announced the first of the individual investigator awards. Two grants from the TTUHSC School of Medicine were among the ~ 60 awards made by CPRIT. Only 7% of the > 800 applications in the first round of funding were awarded. TTUHSC SOM grantees are:
Min Kang, Pharm D, Department of Cell Biology & Biochemistry. Dr. Kang's grant is to study molecular mechanisms of resistance to an exciting new type of anti-cancer drugs known as Bcl-2 inhibitors.
Guillermo Altenberg, MD PhD, Department of Cell Physiology and Molecular Biophysics, together with Ina Urbatsch, PhD, Department of Cell Biology & Biochemistry. Their grant will study the molecular mechanisms of novel inhibitors of a molecule that counters anti-cancer drugs by pumping them out of the cell that is known as MDR-1.